The erbB2 results were very similar in the three groups of familial cases, with 18.6%, 15.1% and 17.4% of the BRCA1, BRCA2 and non-BRCA1/2 tumours, respectively, expressing the erbB2 antigen (Table 2). Here, ERBB2 is linked to neoplasm.